Will It Shed the ‘COVID-19 Vaccine Company’ Label? SK Bioscience’s First Report Card for Next Year

조선일보

Lean Right

Factuality

Ownership

SK Bioscience will release the results of its global Phase 3 clinical trials for the pneumococcal vaccine ‘GBP410’ in the second half of next year. This marks the first test to gauge whether the company can transcend being merely a ‘COVID-19 vaccine company’ since gaining recognition during the pandemic. GBP410 is a pneumococcal vaccine that covers 21 serotypes. According to the company, it is expected to prevent approximately 64% of causative s…